

# Arnaud Del Bello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8672641/publications.pdf>

Version: 2024-02-01

49  
papers

2,338  
citations

394286

19  
h-index

223716

46  
g-index

49  
all docs

49  
docs citations

49  
times ranked

3862  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 322-323.	2.6	120
2	Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. <i>American Journal of Transplantation</i> , 2022, 22, 1430-1441.	2.6	5
3	Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients. <i>American Journal of Transplantation</i> , 2022, 22, 1467-1474.	2.6	37
4	Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 354.	2.1	8
5	Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients. <i>Liver International</i> , 2022, 42, 1132-1143.	1.9	4
6	Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2022, 7, 1241-1247.	0.4	25
7	Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. <i>Transplantation Direct</i> , 2022, 8, e1248.	0.8	25
8	The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
9	Kidney transplantation during the COVID-19 pandemic: Potential long-term consequences of an early post-transplant infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13446.	0.7	4
10	Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?. <i>American Journal of Transplantation</i> , 2021, 21, 1641-1649.	2.6	26
11	Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study. <i>Clinical Transplantation</i> , 2021, 35, e14207.	0.8	4
12	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.	2.6	8
13	High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1704-1709.	0.4	87
14	Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. <i>American Journal of Transplantation</i> , 2021, 21, 2616-2618.	2.6	8
15	Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 661-662.	13.9	728
16	Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. <i>Annals of Internal Medicine</i> , 2021, 174, 1336-1338.	2.0	122
17	Fatal encephalitis and Borna Disease Virus seropositivity in two kidney transplant patients living in the same nonendemic area. <i>Transplant Infectious Disease</i> , 2021, 23, .	0.7	5
18	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. <i>Kidney International</i> , 2021, 100, 915-927.	2.6	4

#	ARTICLE	IF	CITATIONS
19	Outcomes of solid organ transplant recipients with invasive aspergillosis and other mold infections. <i>Transplant Infectious Disease</i> , 2020, 22, e13200.	0.7	9
20	Outcome of Liver Transplant Patients With Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies. <i>Liver Transplantation</i> , 2020, 26, 256-267.	1.3	17
21	Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1365-1374.	2.6	20
22	T cell reconstitution after lymphocyte depletion features a different pattern of inhibitory receptor expression in ABO-versus HLA-incompatible kidney transplant recipients. <i>Clinical and Experimental Immunology</i> , 2020, 200, 89-104.	1.1	4
23	Possible patient to patient transmission of progressive multifocal leukoencephalopathy among kidney-transplant patients. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 473-474.	0.3	1
24	Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. <i>Kidney International Reports</i> , 2020, 5, 2202-2211.	0.4	6
25	Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 501-503.	2.0	21
26	A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. <i>Kidney International Reports</i> , 2020, 5, 1207-1217.	0.4	1
27	Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic. <i>American Journal of Transplantation</i> , 2020, 20, 2962-2963.	2.6	7
28	Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1752-1753.	2.6	9
29	Anti-IL-2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative midterm outcomes after ABO-incompatible kidney transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13681.	0.8	4
30	Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy. <i>Emerging Infectious Diseases</i> , 2019, 25, 2145-2147.	2.0	24
31	No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents. <i>Transplant Infectious Disease</i> , 2019, 21, e13093.	0.7	4
32	Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , 2019, 36, 462-477.	1.3	25
33	Recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. <i>American Journal of Transplantation</i> , 2018, 18, 525-526.	2.6	7
34	Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. <i>Transplant International</i> , 2018, 31, 408-423.	0.8	22
35	Improved Fetal Hemoglobin With mTOR Inhibitor-Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease. <i>American Journal of Transplantation</i> , 2017, 17, 2212-2214.	2.6	24
36	Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. <i>Liver Transplantation</i> , 2017, 23, 880-886.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 887-893.	1.4	13
38	Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. <i>Case Reports in Transplantation</i> , 2017, 2017, 1-6.	0.1	8
39	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 2816-2835.	2.6	451
40	Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation. <i>Transplantation</i> , 2016, 100, 159-166.	0.5	59
41	Donor-specific antibodies and liver transplantation. <i>Human Immunology</i> , 2016, 77, 1063-1070.	1.2	44
42	Maintaining immunosuppressive treatment after early allograft nephrectomy does not reduce the risk of anti-HLA allosensitization. <i>Transplant International</i> , 2015, 28, 1113-1115.	0.8	4
43	<i>De novo</i> donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. <i>Transplant International</i> , 2015, 28, 1371-1382.	0.8	70
44	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. <i>Journal of Transplantation</i> , 2015, 2015, 1-5.	0.3	5
45	Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results. <i>Transplant Immunology</i> , 2015, 32, 151-155.	0.6	18
46	Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. <i>Transplant Infectious Disease</i> , 2015, 17, 279-283.	0.7	55
47	Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. <i>Journal of Hepatology</i> , 2014, 61, 963-965.	1.8	8
48	Prevalence, Incidence and Risk Factors for Donor-Specific Anti-HLA Antibodies in Maintenance Liver Transplant Patients. <i>American Journal of Transplantation</i> , 2014, 14, 867-875.	2.6	96
49	Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1310-1319.	2.2	77